| HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL M Kalac, L Scotto, E Marchi, J Amengual, VE Seshan, G Bhagat, ... Blood, The Journal of the American Society of Hematology 118 (20), 5506-5516, 2011 | 173 | 2011 |
| Outcomes of patients with double-hit lymphoma who achieve first complete remission DJ Landsburg, MK Falkiewicz, J Maly, KA Blum, C Howlett, T Feldman, ... Journal of Clinical Oncology 35 (20), 2260, 2017 | 164 | 2017 |
| A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma JE Amengual, R Lichtenstein, J Lue, A Sawas, C Deng, E Lichtenstein, ... Blood, The Journal of the American Society of Hematology 131 (4), 397-407, 2018 | 133 | 2018 |
| Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial OA O'Connor, JK Lue, A Sawas, JE Amengual, C Deng, M Kalac, L Falchi, ... The Lancet Oncology 19 (2), 257-266, 2018 | 121 | 2018 |
| Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study OA O’Connor, L Falchi, JK Lue, E Marchi, C Kinahan, A Sawas, C Deng, ... Blood, The Journal of the American Society of Hematology 134 (17), 1395-1405, 2019 | 116 | 2019 |
| Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412 GS Nowakowski, F Hong, DW Scott, WR Macon, RL King, TM Habermann, ... Journal of Clinical Oncology 39 (12), 1329, 2021 | 94 | 2021 |
| Emerging EZH2 inhibitors and their application in lymphoma JK Lue, JE Amengual Current hematologic malignancy reports 13, 369-382, 2018 | 93 | 2018 |
| Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor ACY-1215 and bortezomib is synergistic in lymphoma JE Amengual, P Johannet, M Lombardo, K Zullo, D Hoehn, G Bhagat, ... Clinical Cancer Research 21 (20), 4663-4675, 2015 | 88 | 2015 |
| Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era JN Gerson, E Handorf, D Villa, AS Gerrie, P Chapani, S Li, LJ Medeiros, ... Journal of Clinical Oncology 37 (6), 471-480, 2019 | 87 | 2019 |
| A phase 1/2 trial of ublituximab, a novel anti‐CD 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to … A Sawas, CM Farber, MT Schreeder, MY Khalil, D Mahadevan, C Deng, ... British journal of haematology 177 (2), 243-253, 2017 | 72 | 2017 |
| Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas JK Lue, SA Prabhu, Y Liu, Y Gonzalez, A Verma, PS Mundi, N Abshiru, ... Clinical Cancer Research 25 (17), 5271-5283, 2019 | 71 | 2019 |
| Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma JE Amengual, S Clark-Garvey, M Kalac, L Scotto, E Marchi, E Neylon, ... Blood, The Journal of the American Society of Hematology 122 (12), 2104-2113, 2013 | 68 | 2013 |
| The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T‐cell lymphoma E Marchi, KM Zullo, JE Amengual, M Kalac, D Bongero, CM McIntosh, ... British journal of haematology 171 (2), 215-226, 2015 | 59 | 2015 |
| Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma S Jain, X Jirau-Serrano, KM Zullo, L Scotto, CF Palermo, SA Sastra, ... Clinical Cancer Research 21 (9), 2096-2106, 2015 | 57 | 2015 |
| Aurora A kinase inhibition selectively synergizes with histone deacetylase inhibitor through cytokinesis failure in T-cell lymphoma KM Zullo, Y Guo, L Cooke, X Jirau-Serrano, M Mangone, L Scotto, ... Clinical Cancer Research 21 (18), 4097-4109, 2015 | 51 | 2015 |
| High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy L Falchi, A Sawas, C Deng, JE Amengual, DS Colbourn, EA Lichtenstein, ... Journal of hematology & oncology 9, 1-4, 2016 | 44 | 2016 |
| Addition of lenalidomide to R‐CHOP (R2CHOP) improves outcomes in newly diagnosed diffuse large B‐cell lymphoma (DLBCL): first report of ECOG‐ACRIN1412 a randomized phase 2 US … GS Nowakowski, F Hong, DW Scott, R Macon, RL King, TM Habermann, ... Hematological Oncology 37, 37-38, 2019 | 41 | 2019 |
| First‐in‐class selective HDAC6 inhibitor (ACY‐1215) has a highly favorable safety profile in patients with relapsed and refractory lymphoma JE Amengual, JK Lue, H Ma, R Lichtenstein, B Shah, S Cremers, S Jones, ... The Oncologist 26 (3), 184-e366, 2021 | 35 | 2021 |
| Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure EC Ayers, S Li, LJ Medeiros, DA Bond, KJ Maddocks, P Torka, ... Cancer 126 (2), 293-303, 2020 | 32 | 2020 |
| Mechanisms of acquired drug resistance to the HDAC6 selective inhibitor ricolinostat reveals rational drug-drug combination with ibrutinib JE Amengual, SA Prabhu, M Lombardo, K Zullo, PM Johannet, ... Clinical cancer research 23 (12), 3084-3096, 2017 | 27 | 2017 |
